Leucemia linfoblastica acuta: Storia di un successo

Rivista Italiana di Pediatria

Volumn 24, Issue 4, 1998, Pages 544-548

  Masera, G ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Acute lymphoblastic leukemia; Success

Indexed keywords

EID: 33747031688     PISSN: 03925161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in acute leukemia in children produced by folie acid antagonist, 4-Aminoptcroyl-glittamic acid (Aminopterin). N Engl J Med 1948;238:787.
2. Sansone G. Pathomorphosis of acute infantile leukemia treated with modern therapeutic agents; «meningoleukemia» andFrolich's obesity. Annales Paediatrici, vol. 183, n.l: 33-42.
3. Pinkel D. History and development of total therapy for acute lymphocitic leukemia. In Leukemia Research: advances in cell biology and treatment: 189-201,1983.
4. Nachman J, Sather HN, Gaynon PS, et al. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children 's Cancer Group. J Clin Oncol 1997; 15:2222-30.
5. Chessels JM, Hardisty RM, Rapson N, et al. Acute lymphoblastic leukemia in children: classification and prognosis. Lancet 1977, ii: 1307-1309.
6. Sallan SE, Ritz J, Pesando J, et al. Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. Blood 1988;55:395-402.
7. Morgan E, Hsu CCs. Prognostic significance of the acute lymphoblastic leukemia (ALL) cell-associated antigen in children with null-cell ALL. Am J Pediatr Hematol Oncol 1980;2:99-102.
8. Pui C-H, Behm FG, Crist \VM. Clinical and biologic relevance of immunologie marker studies in chilhood acute lymphoblastic leukemia. Blood 1993;82:343-362.
9. Reiter A, Schrappe M, Ludwig W-D, et al. Favorable outcome ofB-cell acute lymphoblastic leukemia in chilhood: a report of three consecutive studies of the BFM group. Blood 1992;80:2471-8.
10. Reiter A, Schrappe M, Ludwig W-D, et al. Chemotherapy in998unselected childhood acute lymphoblastic leukemia patients: results and conclusions of'the multicenter trialALL-BFM 86. Blood 1994;84:3122-33.
11. Pui C-H. Childhood leukeinias. N Engl J Med 1995;24:1618-1630.
12. Sallan SE, Hitchock-Bryan S, Gelber R, et al. Influence of 'intensive asparaginase in the treatment of 'childhood nonT-cell acute lymphoblastic leukemia. Cancer Res 1983;43:5601-5607.
13. Freeman AI, Wcinberger v, Brecker ML, et al. Comparison of intermediate dose Methotrexate with cranial irradiation for the post-induction treatment of acute lymphoblastic leukemia in children. N Engl J Med 1983:308:477-488.
14. Slordhal L, Kolmann S, Kog S, et ai. High-dose methotrexate therapy (6-8 gr/mq) in chilhood malignancies: clinical tolerability and pliarmacokinetics. Pediatr Hematol Oncol 1987;4:32-42.
15. Tubergen D, Gilchrist G, Sather H, et al. Intrathecal methotrexate provides adequate central nervous system therapy in acute lymphoblastic leukemia patients with intermediate risk features and age of less than ten years. Proc Am Assoc Cancer Res Am Soc Clin Oncol 1988;7:178.
16. Pullen J, Boyett j, Frankel L, et al. Extended triple intrathecal (TIT) chemotherapy provides effective central nen-otis system prophylaxis for both good and poor prognosis patients with non-T, non-B acute lyiiipliocylic leukemia: substitution of intermediate dose methotrexate for TIT after consolidation provides less effective protection for the CNS. Proc Am Assoc Cancer Res Am Soc Clin Oncol 1988;7:176.
17. Conter V, Aricö M, Valsecchi, et al. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in intermediate risk ALL children treated with BFM-based intensive chemoterapy. J Clin Oncol 1995;13:2497-2502.
18. Uderzo C, Rondelli R, Dini G, et al. High-dose vincristine,fractioned total-body irradiation andcyclophosphamide regimen in allogeneic bone marrow transplantation for chilhood acute lymphoblastic leukemia in second remission: a 7-year Italian multicentre study. Br J Haematol, 1995;89:790-797.
19. Uderzo C, Valsecchi MG, Balduzzi A, et al. Allogeneic bone marrow transplantation versus chemotherapy in high-risk childhood acute lymphoblastic leukemia in first remission. Br J Haematol 1997;96:387-394.
20. Percz-Atayde AR, Sallan SE, Tedrow U, et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. AmJPathoI1997;150:815.
21. Borkhardt A, Cazzaniga G, Viehmann S, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian mullicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the BerlinFrankfurt-Munster Study Group. Blood 1997;90:571-c)).
22. Masera G, Gadner H, Kamps WA, et al. The treatment of childhood acute lymphoblastic leukemia. Int. J Paed Hematol Oncol: 1998; Vol.5 (2-4):141-144.
23. Wagner HP, Antic V. The problem of pédiatrie malignancies in the developing world. Derived from Challenges and opportunities in pédiatrie oncology: vol.824:193-204.